PT  - JOURNAL ARTICLE
AU  - Marta Carvalho
AU  - Bruno Sepodes
AU  - Ana Paula Martins
TI  - Patient access to gene therapy medicinal products: a comprehensive review
AID  - 10.1136/bmjinnov-2020-000425
DP  - 2021 Jan 01
TA  - BMJ Innovations
PG  - 123--134
VI  - 7
IP  - 1
4099  - http://innovations.bmj.com/content/7/1/123.short
4100  - http://innovations.bmj.com/content/7/1/123.full
SO  - BMJ Innov2021 Jan 01; 7
AB  - Background Gene therapies have the potential to be a curative approach to a large number of genetic diseases. However, granting of a positive marketing authorisation does not equal patient access to therapy.Objectives The purpose of this paper is to identify a full set of hurdles potentially preventing patient access to gene therapies based on the available literature.Methods A review of the literature using systematic approach in two distinct databases was performed by identifying relevant, peer-reviewed publications, between 2012 and 2018.Results Seven major topics were identified as potential patient access hurdles, namely affordability, assessment of value, development of therapy, ethical/social factors, evidence generation, operational implementation and regulatory hurdles. From these, 25 additional subthemes were further identified. The most frequently mentioned obstacle in the literature is related to the affordability aspect especially focusing on high cost of therapy (84%) and therapy payment/reimbursement (51%). Importantly, the evidence generation focusing on limited trial outcomes (81%) seems as a strong obstacle in patient access to these therapies.Conclusions A growing number of gene therapies are expected to be developed and made available to patients and healthcare professionals. Improvement of patient access to gene therapies can only be achieved by understanding all hurdles, in a complete and integrated fashion, so that strategies are timely established to ensure gene therapies’ benefits are provided to patients and to the society.